Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases
Gıancarlo Comı(Casa di Cura Columbus), Angelo Ghezzi, P. Perini(University of Padua), Lucia Moiola(Vita-Salute San Raffaele University), Roberto Bergamaschi(Fondazione Istituto Neurologico Nazionale Casimiro Mondino), Leandro Provinciali(Ospedali Riuniti di Ancona), Elio Scarpini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Giulia Coarelli(Centre National de la Recherche Scientifique), Alessandra Lugaresi(Istituto delle Scienze Neurologiche di Bologna), Simona Malucchi(Ospedale San Luigi Gonzaga), Maria Pia Amato(University of Florence), Elisabetta Capello(Ospedale Policlinico San Martino), Marco Rovaris(San Raffaele University of Rome), Francesco Patti(University of Catania), Giuseppe Salemi, Alessia Bianchi(Queen Mary University of London), Giacomo Lus(University of Campania "Luigi Vanvitelli"), Antonio Gallo(University of Campania "Luigi Vanvitelli"), Eleonora Cocco(University of Cagliari), Mariaemma Rodegher(University of Milan), M. R. Tola(Vita-Salute San Raffaele University), M. R. Rottoli(Ospedale Papa Giovanni XXIII), Pietro Annovazzi(Vita-Salute San Raffaele University), Nicola De Rossi
Cited by 27
Related Papers
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
|The Lancet|2001|1.1k
Multiple Sclerosis Severity Score
|Neurology|2005|959
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study
|The Lancet Respiratory Medicine|2020|738